Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

It is believed most humans are ... First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully ...

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...

clinical and neuropathological research have revolutionized our understanding of the pathophysiology of Alzheimer's disease, yet at the present moment the only drugs licensed for treatment are ...

The treatment aims to slow the spread ... disorder that accounts for 60-80 percent of dementia cases worldwide. Currently, there is no cure for Alzheimer's disease, which eventually leads to ...

Currently, there is no cure for Alzheimer's disease, which eventually leads to death after a long period of cognitive decline and loss of the ability to perform daily tasks. With the global population ...

It is believed most humans are ... First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully ...

This reactivation triggered inflammation, beta-amyloid plaque build-up, and the formation of harmful tau proteins, signature markers of Alzheimer's disease. There was also evidence of diminished ...

While many people take supplements for brain health, the research supporting supplemental nutrients' effects on brain health ...

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...